TELA Bio Reports 2025 Results as Soft Tissue Reconstruction Market Shifts
TELA Bio reported its fourth-quarter and full-year 2025 financial results, highlighting the steady adoption of its OviTex reinforced tissue matrices. The report comes amid a busy earnings cycle that also saw leadership changes at Reed's Inc. and financial updates from Intrusion Inc.